meglumine Report issue

Small molecule Imaging Approved FDA
AACT ChEMBL PubChem

Active Ingredient History

NOW
  • Now
Meglumine (N-methyl-D-glucamine) is a poorly metabolized derivative of sorbitol that has regulatory acceptance as a benign excipient for drug formulation to increase aqueous solubility of lipophilic drugs and improve their absorption. In conjugated form meglumine is used as a contrast agent.   NCATS

Chemistry

  • SMILES: CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
  • InChIKey: MBBZMMPHUWSWHV-BDVNFPICSA-N
  • Mol. Mass: 195.2136
  • ALogP: -3.36
  • ChEMBL Molecule:
    meglumine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Parenteral
  • Pro Drug: No

Combination drugs

( calcium, meglumine, metrizoic acid )

Alternative names

meglumine

Organizations (26)

Research & Development (25)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Contrast Media (approved 1974)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Acidosis (Phase 2)

Influenza, Human (Phase 3)

Leishmaniasis (Phase 2)

Leishmaniasis, Cutaneous (Phase 4)

Leishmaniasis, Mucocutaneous (Phase 2/Phase 3)

Leishmaniasis, Visceral (Phase 4)

Respiratory Tract Infections (Phase 3)

Safety (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial Organizations: 25

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue